טוען...
Cyclo-oxygenase-2 inhibitors or nonselective NSAIDs plus gastroprotective agents: what to prescribe in daily clinical practice?
BACKGROUND: Two strategies for prevention of upper gastrointestinal (UGI) events for non-selective (ns)NSAID users are replacement of the nsNSAID by a cyclo-oxygenase-2-selective inhibitor (coxib) or co-prescription of a gastroprotective agent (GPA). AIM: To identify whether and in whom either of th...
שמור ב:
Main Authors: | , , , , , , , , , , |
---|---|
פורמט: | Artigo |
שפה: | Inglês |
יצא לאור: |
2013
|
נושאים: | |
גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3687334/ https://ncbi.nlm.nih.gov/pubmed/23710837 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/apt.12348 |
תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|